|
| Press Releases |
|
 |
|
| Wednesday, May 9, 2018 |
|
|
Helsinn Group announces the launch of the IV formulation of AKYNZEO(R) (fosnetupitant/palonosetron) in the United States |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the intravenous formulation of AKYNZEO(R) (a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) for injection has been launched in the United States by its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc.. more info >> |
|
| Friday, April 20, 2018 |
|
|
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of AKYNZEO(R) (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing CINV. more info >> |
|
| Tuesday, April 17, 2018 |
|
|
Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy |
| Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma focused on oncology and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announce that they are collaborating on the development of an investigational highly-selective RET inhibitor TAS0286/HM05, being evaluated in non-small cell lung cancer and other carcinomas. more info >> |
|
| Wednesday, March 28, 2018 |
|
|
Helsinn Healthcare S.A.: Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced |
| Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announced that Lorenzo Pradella of GreenBone Ortho, srl and Gitte Pedersen of Genomic Expression, Inc. have been chosen as winners of the first ever Lyfebulb-Helsinn Innovation Awards in Oncology. more info >> |
|
| Friday, March 2, 2018 |
|
|
Helsinn Healthcare S.A.: Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology |
| Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announce the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. more info >> |
|
| Tuesday, October 17, 2017 |
|
|
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces the approval of Helsinn Pharmaceuticals (Beijing) Co. Ltd., Shanghai branch, on August 7, 2017 by the Shanghai Administration for Industry and Commerce with a 30-year term. The full address and contact details of the Shanghai branch are found at the end of this announcement. more info >> |
|
| Friday, September 9, 2016 |
|
|
Helsinn and PatientsLikeMe Announce Results of NSCLC Patient Survey on Weight Loss |
| Helsinn Therapeutics (U.S.) Inc., the pharmaceutical group focused on building quality cancer care, and patient network PatientsLikeMe have unveiled findings from an online survey that captured experiences and insights about unintended weight loss and its burden among 95 patients living with non-small cell lung cancer. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
百年金字招牌煥新顏：同仁堂醫養啟動招股 四大投資邏輯錨定"中醫醫療服務龍頭"
Mar 20, 2026 22:21 HKT/SGT
|
|
|
百年金字招牌焕新颜：同仁堂医养启动招股 四大投资逻辑锚定"中医医疗服务龙头"
Mar 20, 2026 22:21 HKT/SGT
|
|
|
FILMART and EntertainmentPulse draw about 8,000 industry participants
Mar 20, 2026 20:40 HKT/SGT
|
|
|
康哲藥業業績拐點確立：創新藥與獨家藥接棒增長 新藥進入密集兌現期
Mar 20, 2026 20:08 HKT/SGT
|
|
|
TANAKA Announces Executive Appointments
Mar 20, 2026 20:00 HKT/SGT
|
|
|
127家醫療企業排隊赴港 同仁堂醫養攜連年穩增營收開啟招股
Mar 20, 2026 18:15 HKT/SGT
|
|
|
127家医疗企业排队赴港 同仁堂医养携连年稳增营收开启招股
Mar 20, 2026 18:15 HKT/SGT
|
|
|
「国家新发展 香港新机遇 十五五开局研讨会」圆满结束 逾500名内地企业代表及港商共谋香港机遇
Mar 20, 2026 16:28 HKT/SGT
|
|
|
「國家新發展 香港新機遇 十五五開局研討會」圓滿結束 逾500名內地企業代表及港商共謀香港機遇
Mar 20, 2026 16:28 HKT/SGT
|
|
|
同仁堂醫養今日招股：萬億中醫賽道迎來行業龍頭 打造「醫養結合」新標杆
Mar 20, 2026 15:04 HKT/SGT
|
|
|
同仁堂医养今日招股：万亿中医赛道迎来行业龙头 打造"医养结合"新标杆
Mar 20, 2026 15:04 HKT/SGT
|
|
|
MarketingPulse及eTailingPulse吸引逾1,700名业界人士参与 反应热烈 匯聚全球电商及品牌领袖 探讨AI、数据与美学智慧 打造新增长方程式
Mar 20, 2026 11:42 HKT/SGT
|
|
|
MarketingPulse及eTailingPulse吸引逾1,700名業界人士參與 反應熱烈 匯聚全球電商及品牌領袖 探討AI、數據與美學智慧 打造新增長方程式
Mar 20, 2026 11:42 HKT/SGT
|
|
|
MarketingPulse and eTailingPulse attract more than 1,700 industry professionals
Mar 20, 2026 11:42 HKT/SGT
|
|
|
創新實業去年淨利飆升三成 獲納入恒指成份股顯實力
Mar 20, 2026 11:42 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
